As part of this study, we updated the Hebon questionnaire, making it suitable for families carrying (likely) pathogenic variants in genes other than BRCA1 and BRCA2, as currently everyone who had breast and/or ovarian cancer genetic panel testing, regardless of their own test result, is eligible to participate. The gene discussed is BRCA2; the disease is ovarian cancer.